NCT07019766Recruiting
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
Source: ClinicalTrials.gov · Last updated 17 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The objectives of this study are to investigate the incidence and risk factors of large granular lymphocytic leukemia (LGLL) and to analyze the treatment effectiveness, patient prognosis, and healthcare costs in China. 1. Analyze the demographic and clinical characteristics of patients with LGLL, including sex, age, disease severity, and other relevant factors. 2. Examine disease features of LGLL patients, such as biochemical and hematological indicators, LGL counts, clonality, bone marrow pathology, and cytogenetics 3. Assess treatment patterns and real-world effectiveness in LGLL patients. 4. Evaluate clinical outcomes, including hematologic response, relapse, and mortality 5. Investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 9999 (estimated)
- First submitted
- 28 May 2025
- Start date
- Jan 2000
- Primary completion date
- Dec 2070
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Diseases
- Childhood cancers
- NCT number
- NCT07019766
What you commit to
- Study type: Observational
- Planned participants: 9999
- From Jan 2000 to the primary completion date, Dec 2070
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subject with alcohol or drug dependence that may reduce their compliance with the study.
Other
- Subject unlikely to be available for long-term follow-up for any reason (e.g., inability to obtain follow-up data or presence of severe comorbidities).
- Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.
Who the study is looking for
- Subjects diagnosed with LGLL.
- Subjects treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2000.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Red Blood Cell Diseases Center and Regenerative Medicine Center Coordinator of this site? Confirm its status | Tianjin | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.